CNMD - CONMED Corporation
| Previous Close | 84.29 |
| Open | 84.38 |
| Bid | 83.95 x 800 |
| Ask | 83.97 x 800 |
| Day's Range | 83.61 - 85.14 |
| 52 Week Range | 56.91 - 88.71 |
| Volume | 188,101 |
| Avg. Volume | 233,606 |
| Market Cap | 2.371B |
| Beta (3Y Monthly) | 0.70 |
| PE Ratio (TTM) | 77.75 |
| EPS (TTM) | 1.08 |
| Earnings Date | Jul 31, 2019 |
| Forward Dividend & Yield | 0.80 (0.95%) |
| Ex-Dividend Date | 2019-06-13 |
| 1y Target Est | 90.40 |
- Zacks•6 days ago
LH vs. CNMD: Which Stock Is the Better Value Option?
LH vs. CNMD: Which Stock Is the Better Value Option?
- Simply Wall St.•8 days ago
Do Investors Have Good Reason To Be Wary Of CONMED Corporation's (NASDAQ:CNMD) 0.9% Dividend Yield?
Could CONMED Corporation (NASDAQ:CNMD) be an attractive dividend share to own for the long haul? Investors are often...
- Zacks•19 days ago
Here's Why You Should Invest in CONMED (CNMD) Stock Now
CONMED (CNMD) continues to benefit from robust international sales, broad product portfolio and persistent focus on R&D.
- Zacks•21 days ago
Myriad Genetics' Elevate 2020 Plan Holds Promise Amid Issues
Myriad Genetics (MYGN) unveils an 'Elevate 2020' program that aims to generate $50 million in incremental operating income by fiscal 2020.
- Zacks•21 days ago
Medtronic's Titan Spine Buyout to Boost Spine Surgery Range
Medtronic's (MDT) comprehensive biologics portfolio clubbed with Titan Spine's surface-enhanced titanium implants can enhance patient outcomes in spinal procedures.
- Business Wire•22 days ago
CONMED Corporation to Announce Second Quarter 2019 Financial Results on July 31, 2019
CONMED Corporation (CNMD) today announced that it will report financial results for the second quarter of 2019 after the market close on Wednesday, July 31, 2019. The Company’s management will host a conference call at 4:30 p.m. ET that same day to discuss the results. To participate in the conference call, dial 844-889-7792 (domestic) or 661-378-9936 (international) and refer to the passcode 6992059.
- Zacks•22 days ago
Walgreens Gains on Strategic Deals, Margin Pressure Remains
Walgreens Boots' (WBA) Retail Pharmacy USA division is witnessing comparable prescription growth and also benefiting from a strong retail prescription market.
- Zacks•22 days ago
Thermo Fisher's Unit Sale May Not Ail Specialty Diagnostics
The Anatomical Pathology business of Thermo Fisher (TMO) belongs to its Specialty Diagnostics segment that serves customers across healthcare and clinical laboratories.
- Zacks•22 days ago
Here's Why You Should Hold Varian Medical (VAR) Stock Now
Varian (VAR) expects the Cancer Treatment Services International buyout to prove accretive to earnings per share during fiscal 2021.
- Zacks•25 days ago
Amedisys Rides on New Buyouts, Strength in Personal Care Arm
Amedisys' (AMED) recently-integrated Personal Care segment is attaining stability and living up to expectation.
- Zacks•25 days ago
Veeva's Vault eTMF Implemented by South Korea's Celltrion
Management at Veeva (VEEV) expects Vault subscription revenues to grow a significant 40% in fiscal 2020.
- Simply Wall St.•26 days ago
A Closer Look At CONMED Corporation's (NASDAQ:CNMD) Uninspiring ROE
Many investors are still learning about the various metrics that can be useful when analysing a stock. This article is...
- Zacks•26 days ago
Patterson Companies' (PDCO) Earnings Miss Estimates in Q4
Patterson Companies' (PDCO) Q4 results benefit from higher revenues, gross margin expansion and solid show by Animal Health segment.
- Zacks•26 days ago
Varian (VAR) & Tennessee Oncology to Implement Use of Noona
Varian's (VAR) core Oncology unit gets a boost from the latest collaboration with Tennessee Oncology.
- Zacks•27 days ago
Here's Why You Should Invest in DENTSPLY SIRONA (XRAY) Now
DENTSPLY (XRAY) focuses on innovation through active R&D.
- Zacks•27 days ago
Veeva's Submissions & RIM Implemented by Sumitomo Dainippon
Veeva's (VEEV) flagship Vault platform witnesses robust demand.
- Zacks•29 days ago
Here's Why You Should Buy Masimo (MASI) Stock Right Now
Masimo (MASI) receives FDA clearance for its O3 Regional Oximetry for utilization on neonatal and infant patients.
- Zacks•last month
DaVita Divests DMG to Optum, Boosts Kidney Care Services
The divestment of DMG boosts DaVita's (DVA) core Kidney Care business.
- Zacks•last month
Here's Why You Should Hold PerkinElmer (PKI) Stock for Now
PerkinElmer (PKI) raises earnings per share guidance for 2019.
- Simply Wall St.•last month
CONMED Corporation’s (NASDAQ:CNMD) Investment Returns Are Lagging Its Industry
Today we are going to look at CONMED Corporation (NASDAQ:CNMD) to see whether it might be an attractive investment...
- Business Wire•last month
Dirk Kuyper to Step Down from CONMED Corporation Board of Directors Effective August 1, 2019
CONMED Corporation (CNMD) today announced that independent director, Dirk M. Kuyper, has submitted a notice of resignation, which will take effect on August 1, 2019. “Dirk has been a highly valued voice in the board room for the past six years, and we are grateful for his service to CONMED,” commented Mark Tryniski, Chair of CONMED’s Board of Directors, “Dirk has provided truly valuable insights and strategic direction to management throughout his tenure on the Board, and, on behalf of the entire Board of Directors and our leadership team, I thank Dirk for his important contributions to CONMED’s success.
- Zacks•last month
Here's Why You Should Hold Baxter International (BAX) for Now
Baxter (BAX) expects its bottom line to rise in the second quarter of 2019, courtesy to Renal Care and Clinical Nutrition businesses.
- Markit•last month
See what the IHS Markit Score report has to say about Conmed Corp.
Conmed Corp NASDAQ/NGS:CNMDView full report here! Summary * Bearish sentiment is moderate and increasing * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | NeutralShort interest is moderate for CNMD with between 5 and 10% of shares outstanding currently on loan. This represents an increase in short interest as investors who seek to profit from falling equity prices added to their short positions on June 12. Money flowETF/Index ownership | NeutralETF activity is neutral. ETFs that hold CNMD had net inflows of $1.22 billion over the last one-month. While these are not among the highest inflows of the last year, the rate of inflow is increasing. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
- Zacks•last month
Here's Why Conmed (CNMD) is a Great Momentum Stock to Buy
Does Conmed (CNMD) have what it takes to be a top stock pick for momentum investors? Let's find out.
- Zacks•last month
Baxter's (BAX) New Sharesource 2.0 to Improve PD Treatment
Baxter's (BAX) Sharesource 2.0 provides a more comprehensive patient treatment summary to enable faster clinical insights.
